Abstract：
BACKGROUND: Due to its heterogeneous manifestation an individualized approach to reach therapeutic goals in cervical dystonia (CD) is advantageous.
OBJECTIVE: The aim of the current study was to adapt goal attainment scaling (GAS) to drive the management of CD.
METHODS: 38 patients with CD, regularly treated with botulinum neurotoxin (BoNT), were involved in the current exploratory observational pilot study. GAS, including domains of motor, pain, disability, and psychiatric features, was applied to set up individualized goals with the calculation of initial GAS T-scores. Following at least 4 BoNT injection cycles, patients were reassessed whether they reached the pre-set goals.
RESULTS: The initial GAS T-scores (median: 36.9, range: 22.8-40) significantly improved (P < 0.001) to the end of the study (the median of final GAS T-scores: 50, range: 25.5-63.6).
CONCLUSIONS: The applicability of GAS in CD patients was confirmed, but further large-scale studies are needed refining this innovative approach.
OBJECTIVE: The aim of the current study was to adapt goal attainment scaling (GAS) to drive the management of CD.
METHODS: 38 patients with CD, regularly treated with botulinum neurotoxin (BoNT), were involved in the current exploratory observational pilot study. GAS, including domains of motor, pain, disability, and psychiatric features, was applied to set up individualized goals with the calculation of initial GAS T-scores. Following at least 4 BoNT injection cycles, patients were reassessed whether they reached the pre-set goals.
RESULTS: The initial GAS T-scores (median: 36.9, range: 22.8-40) significantly improved (P < 0.001) to the end of the study (the median of final GAS T-scores: 50, range: 25.5-63.6).
CONCLUSIONS: The applicability of GAS in CD patients was confirmed, but further large-scale studies are needed refining this innovative approach.
摘要：
背景：由于其异质性表现，实现宫颈肌张力障碍（CD）治疗目标的个性化方法是有利的。
目的：本研究的目的是调整目标达成尺度（GAS）以推动CD的管理。
方法：38例CD患者，定期用肉毒杆菌神经毒素（BoNT）治疗，参与了当前的探索性观察性试点研究。GAS,包括运动领域，疼痛,残疾,和精神病学特征，通过计算初始GAST分数来设置个性化目标。在至少4次BoNT注射循环之后,我们重新评估患者是否达到预设目标.
结果：到研究结束时，初始GAST评分（中位数：36.9，范围：22.8-40）显着提高（P<0.001）（最终GAST评分中位数：50，范围：25.5-63.6）。
结论：证实了GAS在CD患者中的适用性，但是需要进一步的大规模研究来完善这种创新方法。
目的：本研究的目的是调整目标达成尺度（GAS）以推动CD的管理。
方法：38例CD患者，定期用肉毒杆菌神经毒素（BoNT）治疗，参与了当前的探索性观察性试点研究。GAS,包括运动领域，疼痛,残疾,和精神病学特征，通过计算初始GAST分数来设置个性化目标。在至少4次BoNT注射循环之后,我们重新评估患者是否达到预设目标.
结果：到研究结束时，初始GAST评分（中位数：36.9，范围：22.8-40）显着提高（P<0.001）（最终GAST评分中位数：50，范围：25.5-63.6）。
结论：证实了GAS在CD患者中的适用性，但是需要进一步的大规模研究来完善这种创新方法。
